Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-038694
Filing Date
2025-03-13
Accepted
2025-03-13 16:02:02
Documents
1
Period of Report
2025-03-11

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3821
  Complete submission text file 0000950170-25-038694.txt   5534
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Issuer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TROVAGENE, INC. 11055 FLINTKOTE AVENUE, SUITE A SAN DIEGO CA 92121
Business Address
Erlander Mark (Reporting) CIK: 0001651537 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35558 | Film No.: 25735638